...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Endoscopy International Open >Endoscopic ultrasound-guided radiofrequency ablation of pancreatic neuroendocrine tumors: a systematic review of the literature
【24h】

Endoscopic ultrasound-guided radiofrequency ablation of pancreatic neuroendocrine tumors: a systematic review of the literature

机译：内镜超声引导射频消融胰腺神经内分泌肿瘤：对文献的系统综述

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background and study aims?Surgery is the mainstay therapy for pancreatic neuroendocrine tumors (P-NETs), but it is associated with significant adverse events (AEs). In recent years, endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) has been described for treating P-NETs. We performed a systematic literature review aimed at exploring the feasibility, effectiveness, and safety of EUS-RFA in treatment of P-NETs. Methods?The literature review was performed in PubMed/MEDLINE, EMBASE, and SCOPUS to identify all case reports of EUS-RFA for treatment of P-NETs. Results?Sixyt-one patients (males 49.2?%, mean age 64.5 years) and 73 tumors (mean size 16?mm, insulinomas 30.1?%) treated with EUS-RFA were included from 12 studies. The overall effectiveness of EUS-RFA was 96?% (75?%?–?100?%) without differences between functional vs. non-functional P-NETs (P?=?0.3) and without relevant issues about safety (mild AEs 13.7?%). While tumor location was not predictive for incomplete/non-response to EUS-RFA, greater tumor dimensions predicted treatment failure (21.8?±?4.71?mm in the non-response group vs 15.07?±?7.34?mm in the response group, P?=?0.048). At ROC analysis, a P-NET size cut-off value ≤18?mm predicted response to treatment, with a sensitivity of 80?% (95?% CI 28.4?%?–?99.5?%), a specificity of 78.6?% (95?% CI 63.2?%?–?89.7?%), a positive predictive value of 97.1?% (95?% CI 84.7?%?–?99.9?%) and a negative predictive value of 30.8?% (95?% CI 9.1?%?–?61.4?%), with an area under the curve of 0.81 (95?% CI 0.67?–?0.95). Conclusions?EUS-RFA is safe and effective for treating P-NETs. It may be reasonable to consider EUS-RFA for small P-NETs, irrespective of the functional status.
机译：背景和研究旨在？手术是胰腺神经内分泌肿瘤（P-NET）的主要疗法，但它与显着不良事件（AES）有关。近年来，已经描述了用于治疗P-Net的内窥镜超声引导的射频消融（EUS-RFA）。我们进行了系统的文献综述，旨在探索EUS-RFA治疗P-Net的可行性，有效性和安全性。方法？文献综述是在PubMed / Medline，Embase和Scopus中进行的，以确定EUS-RFA的所有病例报告，用于治疗P-Net。结果？6岁患者（男性49.2？％，平均年龄64.5岁）和用EUS-RFA处理的73颗肿瘤（平均大小16？mm，胰岛素30.1〜Δ％），包括12项研究。 EUS-RFA的总体效果为96？％（75？％？ - ？100？％），没有功能性与非功能性p-net之间的差异（p？= 0.3），没有关于安全的相关问题（轻度AES 13.7？％）。虽然肿瘤位置对EUS-RFA的不完全/非反应预测，但肿瘤尺寸更大的肿瘤尺寸预测治疗失败（在非响应组中的21.8？±4.71Ω±4.71Ω·mm？±7.34？7.34？7.34？mm。 p？=？0.048）。在ROC分析中，P净尺寸截止值≤18Ω·mm预测对处理的响应，敏感性为80？％（95〜％CI 28.4？％？ - -99.5？％），特异性为78.6？ ％（95？％CI 63.2？％？ - β8.7？％），阳性预测值为97.1〜Δ％（95〜％CI 84.7〜5〜10〜99.9□）和阴性预测值为30.8？％（ 95？％CI 9.1？％？ - α61.4？％），曲线下的面积为0.81（95〜％Ci 0.67？ - 0.95）。结论？EUS-RFA对治疗P-Net是安全可有效的。考虑用于小型P-Net的EUS-RFA可能是合理的，而不管功能状态如何。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号